Capricor Sues Nippon Shinyaku Over Duchenne Therapy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Capricor Therapeutics sues Japanese partner Nippon Shinyaku and its subsidiary NS Pharma over the launch of the Duchenne muscular dystrophy cell therapy deramiocel.
- Capricor alleges the partners botched launch preparations for deramiocel, threatening timely patient access.
- Capricor says the partners' pricing structure could make deramiocel financially inaccessible for many patients.
- Deramiocel is a cell therapy for Duchenne muscular dystrophy that has attracted significant attention from investors and clinicians.
Why it matters: Patients and insurers risk being priced out of a potentially life‑saving Duchenne therapy, while Capricor pushes for a fair launch and pricing, forcing partners to address cost and access barriers.
Ask SkimNews
